TESARO Announces Upcoming Immuno-Oncology Presentations

WALTHAM, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today announced two upcoming presentations related to its immuno-oncology portfolio.

• The Company will participate in the Jefferies 2015 Immuno-Oncology Summit at the Boston Harbor Hotel on April 15, 2015. Mary Lynne Hedley, Ph.D., President and COO of TESARO, will discuss the Company's immuno-oncology programs in a presentation scheduled for 2:00 PM ET.  
• TESARO and AnaptysBio will present preclinical data in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18-22, 2015. Presentation details are as follows: Sunday, April 19, 2015, 1:00 p.m. to 5:00 p.m. ET "Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations" Abstract Number: 271, Location: Section 12. For more information, including the presentation abstract, please visit the AACR website at www.aacr.org.

About TESARO

TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.

CONTACT: For additional information, please contact:
         Jennifer Davis
         1.781.325.1116
         [email protected]

You May Also Be Interested In

• Xsolla Announces Multi-Year Strategic Partnership With the Good Game Club Podcast to Amplify Positive Stories From the Global Games Industry
• Zairoo Entertainment Positions Pan-African Steampunk Fantasy TTRPG as a Major Entertainment IP
• Virtuix Reports First Quarter Fiscal Year 2027 Results as Omni One Orders Increase 150% Following Meta Launch